Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Lawmakers continued to focus on reining in rising drug prices July 27 as a House panel solicited ideas from the FDA and the FTC about how to remove roadblocks to pharmaceutical competition.
Food and Drug Administration Commissioner Scott M. Gottlieb and Federal Trade Commission official Markus Meier told members of the House Judiciary Committee’s Subcommittee on Regulatory Reform, Commercial and Antitrust Law about policies that could help curb certain regulatory abuses in the drug marketplace. Meier is acting director of the FTC’s Bureau of Competition.
The July 27 hearing, titled “Antitrust Concerns and the FDA Approval Process,” gave a lot of play to a possible legislative step, H.R. 2212, the “Creating and Restoring Equal Access to Equivalent Samples Act of 2017” (CREATES Act), to ease some of the competition roadblocks. There’s also a companion bill in the Senate.
The act would address situations where branded drug companies use FDA-required risk evaluation and mitigation strategies (REMS) to deny generic companies access to samples of branded drug products needed to conduct bioequivalence testing for generic approval.
The FDA sometimes requires a REMS plan from a drugmaker to ensure the benefits of the product outweigh its risks.
Subcommittee Chairman Tom Marino (R-Pa.) asked Gottlieb whether the FDA had ever exercised its current authority to levy civil monetary penalties against companies that abuse the REMS system. Gottlieb said the FDA had not levied any fines, adding the statutory authority was very complex and time-consuming with relatively modest penalties.
Gottlieb said there are things the FDA can do within its current authorities, but it can’t fully address some of the commercial restrictions that keep generic companies from getting access to samples. “We need to close loopholes that game rules and hurt consumers,” he said.
“It would seem to me that we could solve that problem if competitors with limited resources had access to the courts,” Marino said.
The CREATES Act would create a cause of action in federal courts for a generic or biosimilar drug applicant to obtain sufficient samples to perform bioequivalency studies. The bill also would make it easier for a generic drug to get FDA approval for a separate REMS program. Marino is the chief House sponsor of the bill, while Sen. Patrick Leahy (D-Vt.) is the sponsor of the Senate version (S. 974).
Meier said the FTC supports the CREATES Act to stem REMS abuses. “The CREATES Act goes a very long way to try and resolve some of these issues,” he said,
The hearing is the fifth in a series convened by the committee on competition in the health-care marketplace.
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
Testimony from the hearing is available at https://judiciary.house.gov/hearing/antitrust-concerns-fda-approval-process/.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)